Masitinib in Patients With Localized, Primary GIST After Complete Surgery and With High Risk of Recurrence

The objective is to compare the efficacy and safety of masitinib at 4.5 mg/kg/day to placebo in the treatment of patients with localized, primary gastrointestinal stromal tumor (GIST) after complete surgery and with high risk of recurrence.